Loading patent…
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsFrerich DE VRIES, Dirk HOERSTERMANN, Ingo LANG, Michael MARK, Randolph SEIDLER, Leo THOMAS
Estimating the term…
The present invention provides a pharmaceutical composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs. The invention further provides respective uses of such compositions and of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or pharmaceutically acceptable forms thereof.
A therapeutic composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable salt thereof as a pharmaceutically active compound for the treatment of a metabolic disorder or metabolic disease in a predominantly carnivorous non-human animal.
A method of treating a metabolic disorder or metabolic disease comprising administering a pharmaceutically effective dose of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine, or a pharmaceutically acceptable salt thereof, to a predominantly carnivorous non-human animal in need thereof such that the severity of one or more clinical symptoms of the metabolic disorder or metabolic disease is reduced.
Dependencies are inferred from the claim text.